SHERIDAN, WYOMING – May 9, 2025 – Enovis Corporation (NYSE: ENOV), a global leader in medical technology, has appointed Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald, who will also join the Enovis Board of Directors following the Company’s 2025 Annual Meeting of Stockholders, succeeds Matt Trerotola, who has announced his retirement. This strategic leadership transition positions Enovis for continued growth and innovation in the medical technology sector.
Strengthening Leadership for Continued Growth
Enovis has made a pivotal leadership change as Damien McDonald, a seasoned executive with over 35 years of experience in the medical device industry, steps into the CEO role. McDonald comes to Enovis from LivaNova, where he served as CEO and significantly enhanced the company’s performance in growth, profitability, and shareholder value. His leadership was marked by a focus on patient-centered care and a results-driven approach that directly aligns with Enovis’ mission of improving patient outcomes through innovation.
Sharon Wienbar, Lead Independent Director at Enovis, expressed confidence in McDonald’s appointment, stating, “On behalf of the Board, I am thrilled to welcome Damien to the Enovis team. His proven track record as a CEO in global medical technology, his deep industry knowledge, and his alignment with our values make him the ideal leader to guide Enovis through its next phase of growth.”
A Track Record of Success in Medical Technology
McDonald’s extensive career includes leadership roles at major medical technology firms. Prior to LivaNova, he held senior positions at Danaher, Zimmer, and Johnson & Johnson’s Ethicon unit. His leadership at LivaNova notably improved the company’s performance in both growth and profitability while fostering a culture centered on patient care—a value McDonald plans to continue at Enovis.
“I am honored to join Enovis at this exciting stage in the Company’s evolution,” said McDonald. “Enovis is a leader in developing innovative technologies that improve patient outcomes, and I look forward to building upon its strong foundation and delivering exceptional value for all our stakeholders.”
Transitioning Leadership and Strategic Direction
Matt Trerotola, the outgoing CEO, has played a crucial role in Enovis' development and operational success over the past decade. His decision to retire will pave the way for McDonald to take Enovis into its next phase of growth. “Damien has the experience, track record, and cultural fit to be a fantastic next leader of Enovis,” stated Trerotola. “I am grateful for the opportunity to lead the Company and look forward to a smooth transition that continues to build on our strategic momentum.”
Alongside the leadership change, Enovis also announced that Sharon Wienbar will assume the role of Independent Chair of the Board following Trerotola’s retirement at the Company’s Annual Meeting.
Financial Outlook and Strategic Focus
Enovis continues to focus on strategic growth and operational excellence. The Company reiterated its guidance for first-quarter revenues, which are expected to fall between $555 million and $563 million, with adjusted EBITDA projected to be in the range of $97 million to $100 million.
This commitment to financial transparency and growth ensures that Enovis remains on track to meet its long-term strategic objectives, supported by its experienced leadership team and a culture of innovation.
Looking Ahead: Enovis' Continued Impact on Patient Care
With McDonald at the helm, Enovis is poised to build on its reputation for innovation and excellence in medical technology. The company remains focused on its mission to create clinically differentiated solutions that drive better patient outcomes and transform workflows in orthopedics and beyond.
Enovis will provide more details on its management transition during its first-quarter 2025 earnings call scheduled for May 8, 2025.
For more information, visit www.enovis.com.